-
Erastin Ferroptosis Workflows for Cancer Research
2026-09-21
Erastin provides an upstream redox-stress challenge for testing cystine metabolism, lipid peroxidation, and genotype-linked tumor vulnerability. This practical guide combines a 10 μM, 24-hour starting workflow with orthogonal validation and translates melanocyte ferroptosis findings into better assay design.
-
Neuroligin 1, PKC, and Repetitive Behavior
2026-09-20
This Advanced Science study identifies a cell-type-specific mechanism linking Neuroligin 1 loss in dorsal-striatal D2 medium spiny neurons to autistic-like self-grooming and digging. Its combination of behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation implicates excessive PKC signaling as a modifiable contributor rather than a standalone explanation for repetitive behavior.
-
Necrostatin 2 (Nec-2): Assay Guide
2026-09-19
A scenario-based guide to using Necrostatin 2 (Nec-2), SKU A3652, to separate necroptosis-related viability loss from nonspecific cytotoxicity. It covers assay controls, compound handling, protocol optimization, interpretation, and practical product-selection criteria.
-
PR-619: Practical DUB Inhibition Workflow
2026-09-18
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for examining ubiquitinated-protein accumulation without directly blocking proteasomal catalytic activity. It is suitable for controlled cell-based ubiquitination and autophagy experiments, but its broad target profile, low-micromolar cytotoxicity, and limited product-dossier evidence require concentration-response testing and parallel viability controls.
-
1-methyl Adenosine: Assay Workflows & Uses
2026-09-18
1-methyl Adenosine supports both mechanistic cell experiments and targeted nucleoside biomarker discovery. Its strongest use-case is a rigorously separated, isotope-diluted LC–MS/MS workflow that distinguishes low-abundance 1-methyl Ado from isomeric RNA metabolites.
-
Oteseconazole (VT-1161): CYP51 Selectivity & Use
2026-09-17
Oteseconazole, also known as VT-1161, is a selective tetrazole CYP51 inhibitor with potent in vitro activity against multiple Candida species. Its strongest evidence supports Candida-focused research and the prevention of recurrent vulvovaginal candidiasis, while activity against Aspergillus fumigatus is limited.
-
Ac-YVAD-CMK for Reliable Pyroptosis Assays
2026-09-17
Learn how Ac-YVAD-CMK (SKU C4810) can help separate caspase-1-dependent cytokine maturation from membrane injury in viability, inflammation, and pyroptosis assays. This scenario-based guide covers controls, formulation, interpretation, and practical product-selection criteria.
-
MK-8745: A Context-Aware Aurora A Workflow
2026-09-16
MK-8745 is a potent and selective Aurora A inhibitor for dissecting mitotic control, apoptosis, and tumor vulnerability. This article translates retinoblastoma findings into practical assay decisions across cell-based and xenograft research while clarifying model selection, endpoint timing, and interpretation limits.
-
Chicken Gasdermins Reveal Caspase-Driven Pyroptosis
2026-09-16
The reference study defines a previously undercharacterized avian pyroptosis pathway by showing that chicken gasdermin A and gasdermin E are cleaved by distinct caspases and that their amino-terminal fragments can damage membranes and restrict bacterial growth. Its combination of biochemical cleavage mapping, cell-based pore-function assays, and infection models provides a framework for studying species-specific gasdermin biology while highlighting the limits of directly transferring mammalian inflammasome models to birds.
-
Auranofin and Metabolic Stress in HCC Research
2026-09-15
Auranofin is a thioredoxin reductase inhibitor that can help researchers interrogate the relationship between redox control and metabolic plasticity in hepatocellular carcinoma. This article translates recent FOXO3/YAP findings into a rigorous, redox-aware assay strategy without overstating unvalidated mechanisms.
-
CHIR-99021 for Stem Cell and Organoid Workflows
2026-09-15
CHIR-99021 (CT99021) provides reversible, selective GSK-3α/β control for tuning pluripotency, endodermal patterning, and organoid maturation. This guide translates atlas-based developmental benchmarking into practical dosing, assay design, and troubleshooting strategies.
-
CCG-1423: A Pathway-Resolved Assay Strategy
2026-09-14
CCG-1423 is a RhoA inhibitor that helps separate MRTF-A transcriptional signaling from ROCK-dependent cytoskeletal remodeling. This article translates recent RhoA/ROCK pathway findings into a practical, evidence-aware framework for cancer research, apoptosis assay design, and cross-domain interpretation.
-
BAX–BAK Mosaic Rings in Apoptotic Mitochondria
2026-09-14
The reference study uses live- and fixed-cell STED microscopy to show that endogenous BAX and BAK assemble into heterogeneous mosaic rings on apoptotic mitochondria, rather than a uniform oligomeric structure. Its findings place BAK recruitment slightly ahead of BAX and show why endogenous protein measurements are essential for interpreting mitochondrial outer membrane permeabilization.
-
Aging Lens Epithelium and Ferroptosis Susceptibility
2026-09-13
Wei and colleagues show that aging lens epithelial cells become unusually vulnerable to ferroptosis, linking age-related redox imbalance, lipid peroxidation, iron accumulation, and impaired glutathione protection. Their combination of human and mouse models, glutathione perturbation, RSL3 and erastin exposure, and transcriptome analysis provides a mechanistic framework for studying ferroptosis in cataractogenesis.
-
WEHI-539: A BCL-XL Inhibitor Workflow
2026-09-12
WEHI-539 is a selective BCL-XL inhibitor for separating BCL-XL dependence from broader apoptotic stress. This practical guide connects dose-response testing, mitochondrial apoptosis assays, cancer stem cell sensitization, and MCL-1-focused combination studies.